Eli Lilly is acquiring Centessa Pharmaceuticals for approximately $6.3 billion, with an additional contingent value right potentially increasing the deal to $7.8 billion. This strategic move aims to bolster Lilly's offerings in the sleep-wake disorder treatment market.
Key takeaways
Quick scan — what you need to know:
- Eli Lilly is acquiring Centessa Pharmaceuticals for approximately $6.3 billion, with an additional contingent value right potentially increasing the deal to $7.8 billion.
- This strategic move aims to bolster Lilly's offerings in the sleep-wake disorder treatment market.
- Centessa's shares saw a significant surge following the announcement.
Background
What led here, in plain terms:
- This strategic move aims to bolster Lilly's offerings in the sleep-wake disorder treatment market.
- Centessa's shares saw a significant surge following the announcement.
Why it matters
Why readers and decision-makers should care:
- Centessa's shares saw a significant surge following the announcement.
- Eli Lilly is acquiring Centessa Pharmaceuticals for approximately $6.3 billion, with an additional contingent value right potentially increasing the deal to $7.8 billion.
- This strategic move aims to bolster Lilly's offerings in the sleep-wake disorder treatment market.